# US 2022/0031848 A1 · Bioink for 3d deposition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031848 A1
- Document ID: US20220031848A1
- Status: Published application
- Kind: A1
- Application number: 17/309,037
- Filed: 2019-10-18
- Published: 2022-02-03
- Earliest claimed: 2018-10-18
- Assignees: Regents of the University of Minnesota
- Applicants: Regents of the University of Minnesota
- Inventors: Brenda M. Ogle; Wei-Han Lin; Molly E. Kupfer; Didarul Bhuiyan
- Web page: https://patentgrep.com/patent/US20220031848A1

## CPC

- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61L 27/52: Hydrogels or hydrocolloids
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 47/02: Inorganic compounds
- A61K 47/24: containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A61L 27/26: Mixtures of macromolecular compounds
- A61L 27/3834: {Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells}
- A61L 27/3895: {using specific culture conditions, e.g. stimulating differentiation of stem cells, pulsatile flow conditions}
- B33Y 70/10: Composites of different types of material, e.g. mixtures of ceramics and polymers or mixtures of metals and biomaterials
- B33Y 80/00: Products made by additive manufacturing
- C12N 5/0657: {Cardiomyocytes; Heart cells}
- A61L 2430/20: for reconstruction of the heart, e.g. heart valves
- B33Y 10/00: Processes of additive manufacturing
- C12N 2506/45: from artificially induced pluripotent stem cells
- C12N 2513/00: 3D culture
- C12N 2533/20: Small organic molecules
- C12N 2533/54: Collagen; Gelatin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- B33Y: ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Example bioinks that can be used for three-dimensional (3D) printing of structures are described. In one example, a bioink composition may include gelatin methacrylate and collagen methacrylate. In some examples, the bioink may also include additional components such as lithium phenyl-2,4,6-trimethylbenzoylphosphinate (LAP). The bioink may promote stem cell differentiation into cardiomyocytes to generate functional 3D structures, for example.

## Claims

### Claim 1

A bioink composition comprising:
gelatin methacrylate; and
collagen methacrylate.

### Claim 2 (depends on 1)

The bioink composition of claim 1, further comprising lithium phenyl-2,4,6-trimethylbenzoylphosphinate.

### Claim 3 (depends on 2)

The bioink composition of claim 2, further comprising a solvent comprising:
mTeSR medium;
acetic acid; and
sodium hydroxide (NaOH).

### Claim 4 (depends on 3)

The bioink composition of claim 3, wherein the solvent comprises approximately:
74 percent weight by volume of mTeSR medium;
20 percent weight by volume of 20 mM acetic acid; and
1 percent weight by volume of 1M NaOH.

### Claim 5 (depends on 1)

The bioink composition of claim 1 4, wherein the bioink composition comprises:
approximately 10 percent weight by volume of the gelatin methacrylate;
approximately 0.25 percent weight by volume of the collagen methacrylate; and
approximately 0.5 percent weight by volume of the lithium phenyl-2,4,6-trimethylbenzoylphosphinate.

### Claim 6 (depends on 1)

The bioink composition of any of claim 1, further comprising at least one of fibronectin or laminin.

### Claim 7 (depends on 1)

The bioink composition of any of claim 1, wherein the composition comprises:
approximately 100 milligrams per milliliter (mg/mL) of the collagen methacrylate;
approximately 2.5 mg/mL of the gelatin methacrylate;
approximately 5 mg/mL of the of the lithium phenyl-2,4,6-trimethylbenzoylphosphinate;
approximately 93.8 micrograms per milliliter (μg/mL) of the fibronectin; and
approximately 93.8 μg/mL of the laminin.

### Claim 8 (depends on 1)

The bioink composition of any of claim 1, further comprising human induced pluripotent stem cells.

### Claim 9 (depends on 8)

The bioink composition of claim 8, wherein the human induced pluripotent stem cells comprise human cardiac fibroblast-derived induced pluripotent stem cells overexpressing Cyclin D2 (CCND2) under the myosin heavy chain (WIC).

### Claim 10 (depends on 8)

The bioink composition of claim 8, wherein the human induced pluripotent stem cells comprise cardiomyocyte precursors.

### Claim 11 (depends on 1)

The bioink composition of any of claim 1, further comprising cardiomyocytes.

### Claim 12 (depends on 1)

The bioink composition of any of claim 1, wherein the bioink composition is configured to promote differentiation of human induced pluripotent stem cells into cardiomyocytes.

### Claim 13

A method comprising:
printing a three-dimensional structure using a bioink composition, wherein the bioink composition comprises gelatin methacrylate and collagen methacrylate.

### Claim 14 (depends on 13)

The method of claim 13, wherein printing the three-dimensional structure using the bioink composition comprises printing the three-dimensional structure using the bioink to create at least one chamber.

### Claim 15 (depends on 13)

The method of claim 13, wherein the three-dimensional structure comprises human induced pluripotent stem cells, and wherein the method further comprises inducing the human induced pluripotent stem cells to differentiate into cardiomyocytes by modulating a Wnt/β-catenin pathway with small molecules.

### Claim 16 (depends on 15)

The method of claim 15, wherein inducing the human induced pluripotent stem cells to differentiate into cardiomyocytes comprises inducing the human induced pluripotent stem cells to differentiate into cardiomyocytes having a cell density approximating cardiac tissue.

### Claim 17 (depends on 13)

The method of claim 13, wherein printing the three-dimensional structure comprising printing the three-dimensional structure using the bioink comprised of the gelatin methacrylate, the collagen methacrylate, and lithium phenyl-2,4,6-trimethylbenzoylphosphinate.

### Claim 18

A bioink composition comprising:
gelatin methacrylate;
collagen methacrylate;
lithium phenyl-2,4,6-trimethylbenzoylphosphinate;
fibronectin;
laminin; and
a solvent comprising mTeSR medium, acetic acid, and sodium hydroxide (NaOH).

### Claim 19 (depends on 18)

The bioink composition of claim 18, wherein the bioink composition comprises:
approximately 10 percent weight by volume of the gelatin methacrylate;
approximately 0.25 percent weight by volume of the collagen methacrylate; and
approximately 0.5 percent weight by volume of the lithium phenyl-2,4,6-trimethylbenzoylphosphinate.
